As of 2016, there was no evidence to support any effect of oral chrysin on testosterone levels, or an any disease-modifying activity with oral or topical formulations. Safety A daily consumed amount of chrysin of 0.5 to 3 g is considered safe. As of 2016, there was no toxicity attributable to chrysin in clinical trials or adverse event reporting. As of 2016, clinical safety issues have not been identified. As of 2016, nonclinical data suggest potential concerns. In 2016, the US Food and Drug Administration did not recommend chrysin be included on the list of bulk drug substances that can be used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act based on consideration of the following criteria: (1) physicochemical characterization; (2) safety; (3) effectiveness; and (4) historical use of the substance in compounding. Research As of 2016, there is no evidence for chrysin being used in human clinical applications. Research showed that orally administered chrysin does not have clinical activity as an aromatase inhibitor. Nanoformulations of polyphenols, including chrysin, are made using various carrier methods, such as liposomes and nanocapsules. Bibliography References Aromatase inhibitors Flavones Flavonoids found in Asteraceae Resorcinols